Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma
University of Foggia, Italy.The Lancet Oncology (Impact Factor: 24.69). 03/2004; 5(2):127-8. DOI: 10.1016/S1470-2045(04)01388-9
[Show abstract] [Hide abstract]
- "An ALC below 1000/μL correlates with shorter survival and lower complete remission rate. Relapses are not uncommon (30% of cases), but often remain sensitive to chemotherapy; allogeneic bone marrow transplants may be effective in refractory cases. Radiation therapy may be necessary after completion of chemotherapy to eliminate residual sites of disease. "
ABSTRACT: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a rare peripheral T-cell lymphoma, accounting for approximately 3% of adult non-Hodgkin lymphomas (NHL). In this report we describe an unusual case of an ALK(+) ALCL, which presented as an aggressive mass involving upper nasal cavity and anterior skull base. The pathogenesis, histopathology with radiologic correlations, and management of this case are reviewed. A 28-year-old Asian female presented with a 3-month history of nasal congestion culminating in epistaxis. Physical examination was notable for a tissue mass obstructing nasal cavity and the sphenoid sinus. Computed tomography (CT) and magnetic resonance (MR) imaging revealed a lesion primarily involving the upper nasal cavity extending intracranially through the cribriform plates into the anterior cranial fossa. Histologic and immunohistochemical analysis of the specimen obtained through a transnasal biopsy revealed an ALK(+) ALCL. The patient underwent two cycles of chemotherapy and focal radiation therapy, achieving minimal residual disease. The patient remained neurologically unchanged with stable minimal residual disease at the 1-year follow-up. To the best of our knowledge, this is the first case of an ALK(+) ALCL that presented as an aggressive upper nasal cavity and anterior skull base lesion. This case report highlights the importance of multi-modality approaches including preoperative imaging and tissue biopsy for definitive diagnosis.Surgical Neurology International 04/2013; 4:57. DOI:10.4103/2152-7806.110656 · 1.18 Impact Factor
Article: Oncogenic protein tyrosine kinases[Show abstract] [Hide abstract]
ABSTRACT: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, the normal role of which remains to be completely elucidated. Although work carried out in mammals suggests a function in neural development, results from studies in Drosophila indicate an additional role in visceral muscle differentiation. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas, while the occurrence of ALK fusion proteins in anaplastic large cell lymphoma (ALCL) has resulted in the identification of the new tumor entity, ALK-positive ALCL. ALK represents one of few examples of a receptor tyrosine kinase implicated in oncogenesis in both haematopoietic and non-haematopoietic tumors, given that ALK fusions also occur in the mesenchymal tumor known as inflammatory myofibroblastic tumor (IMT). The study of ALK fusion proteins, besides demonstrating their importance in tumor development, has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies.Cellular and Molecular Life Sciences CMLS 11/2004; 61(23):2939-2953. DOI:10.1007/s00018-004-4275-9 · 5.81 Impact Factor
- Haematologica 04/2005; 90(3):ECR19. · 5.81 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.